Home » Morning Announcement: Shannon Xinchuang Co., Ltd.’s shareholding company, Yongxi Electronics, has been approved for the first time on the Science and Technology Innovation Board_ Securities Times Network

Morning Announcement: Shannon Xinchuang Co., Ltd.’s shareholding company, Yongxi Electronics, has been approved for the first time on the Science and Technology Innovation Board_ Securities Times Network

by admin
Morning Announcement: Shannon Xinchuang Co., Ltd.’s shareholding company, Yongxi Electronics, has been approved for the first time on the Science and Technology Innovation Board_ Securities Times Network
</p> <p> Morning Announcement: Shannon Xinchuang Co., Ltd.’s shareholding company, Yongxi Electronics, has been approved for the first time on the Science and <a data-ail="331751" target="_blank" href="https://www.breakinglatest.news/category/technology/" >Technology</a> Innovation Board_ Securities Times Network<br />

Home > News > e company

Morning Announcement: Shannon Xinchuang’s shareholding company, Yongxi Electronics Technology Innovation Board, was approved for the first time

2022-02-23 08:09

Source: Securities Times e Company

Author: Lee Jae-san

Securities Times · e company

Lee Jae-san

2022-02-23 08:09

Securities Times e company news, Zhongchen Co., Ltd.: It is expected that the net profit in 2021 will be 78 million yuan to 90 million yuan, a year-on-year decrease of 1.73%-14.84%. The price of the company’s main raw materials, copper and aluminum, leads to an increase in costs, and there is a certain lag in the adjustment of product prices. . Shannon Xinchuang: The application for the initial public offering of shares by the shareholding company Yongsi Electronics and listing on the Science and Technology Innovation Board was reviewed and approved by the Shanghai Stock Exchange. Huadong Medicine: Sino-American Huadong, a wholly-owned subsidiary, signed an exclusive product license agreement with Kiniksa, and obtained the exclusive license for two of Kiniksa’s global innovative products in the field of autoimmunity, Arcalyst and Mavrilimumab, in 24 Asia-Pacific countries and regions (excluding Japan) including China and South Korea. The license, including development, registration and commercialization rights, will be subject to an initial payment of US$22 million, development, registration and sales milestone payments of up to US$640 million, as well as royalties on net sales. (Telephone for reporting illegal and bad information: 0755-83514034 Email: [email protected])

Disclaimer: Securities Times strives for true and accurate information. The content mentioned in the article is for reference only and does not constitute substantive investment advice. Operational risks are based on this.

  • Securities Times APP
  • WeChat public account


  • 4175558

    Morning Announcement: Shannon Xinchuang’s shareholding company, Yongxi Electronics Technology Innovation Board, was approved for the first time

    6885

    e company

    news

    1445

    Lee Jae-san

    2022-02-23

    See also  Juventus, the loss rises to 210 million. Strong passive again this year

    You may also like

    Leave a Comment

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

    Privacy & Cookies Policy